Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q3 2024 financial results with net revenues of $191.2 million, up 6% year-over-year. The company achieved GAAP net income of $40.4 million ($0.78 per share) and adjusted non-GAAP net income of $49.6 million ($0.96 per share). BAQSIMI® contributed significantly with $40.4 million in direct sales, while Primatene MIST® sales increased 5% to $26.1 million. The Board authorized a $50 million increase to the share buyback program. Operating cash flow for the first nine months was $184.4 million.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha riportato i risultati finanziari del terzo trimestre 2024 con ricavi netti di 191,2 milioni di dollari, in aumento del 6% rispetto all'anno precedente. L'azienda ha registrato un reddito netto GAAP di 40,4 milioni di dollari (0,78 dollari per azione) e un reddito netto non-GAAP rettificato di 49,6 milioni di dollari (0,96 dollari per azione). BAQSIMI® ha contribuito in modo significativo con vendite dirette di 40,4 milioni di dollari, mentre le vendite di Primatene MIST® sono aumentate del 5% a 26,1 milioni di dollari. Il Consiglio ha autorizzato un aumento di 50 milioni di dollari al programma di riacquisto delle azioni. Il flusso di cassa operativo per i primi nove mesi è stato di 184,4 milioni di dollari.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reportó los resultados financieros del tercer trimestre de 2024, con ingresos netos de 191,2 millones de dólares, un aumento del 6% en comparación con el año anterior. La compañía logró un ingreso neto GAAP de 40,4 millones de dólares (0,78 dólares por acción) y un ingreso neto ajustado no GAAP de 49,6 millones de dólares (0,96 dólares por acción). BAQSIMI® contribuyó significativamente con 40,4 millones de dólares en ventas directas, mientras que las ventas de Primatene MIST® aumentaron un 5% a 26,1 millones de dólares. La Junta autorizó un aumento de 50 millones de dólares en el programa de recompra de acciones. El flujo de caja operativo para los primeros nueve meses fue de 184,4 millones de dólares.
암파스타 제약 (NASDAQ:AMPH)는 2024년 3분기 재무 결과를 보고하며 순수익이 1억 9120만 달러로 지난해 대비 6% 증가했다고 발표했습니다. 회사는 GAAP 기준 순이익 4040만 달러 (주당 0.78 달러) 및 조정된 비-GAAP 순이익 4960만 달러 (주당 0.96 달러)를 달성했습니다. BAQSIMI®는 4040만 달러의 직접 판매로 큰 기여를 하였고, Primatene MIST®의 판매는 5% 증가하여 2610만 달러에 달했습니다. 이사회는 주식 매입 프로그램에 5000만 달러의 증가를 승인했습니다. 첫 9개월 동안의 운영 현금 흐름은 1억 8440만 달러였습니다.
Amphastar Pharmaceuticals (NASDAQ:AMPH) a annoncé les résultats financiers du troisième trimestre 2024 avec des revenus nets de 191,2 millions de dollars, en hausse de 6 % par rapport à l'année précédente. L'entreprise a réalisé un bénéfice net GAAP de 40,4 millions de dollars (0,78 dollar par action) et un bénéfice net ajusté non-GAAP de 49,6 millions de dollars (0,96 dollar par action). BAQSIMI® a contribué de manière significative avec 40,4 millions de dollars en ventes directes, tandis que les ventes de Primatene MIST® ont augmenté de 5 % pour atteindre 26,1 millions de dollars. Le conseil d'administration a autorisé une augmentation de 50 millions de dollars du programme de rachat d'actions. Le flux de trésorerie d'exploitation pour les neuf premiers mois s'élevait à 184,4 millions de dollars.
Amphastar Pharmaceuticals (NASDAQ:AMPH) hat die finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht, mit einem Nettoumsatz von 191,2 Millionen Dollar, was einem Anstieg von 6% im Vergleich zum Vorjahr entspricht. Das Unternehmen erzielte einen GAAP-Nettoertrag von 40,4 Millionen Dollar (0,78 Dollar pro Aktie) sowie einen angepasstes Non-GAAP-Nettoergebnis von 49,6 Millionen Dollar (0,96 Dollar pro Aktie). BAQSIMI® leistete mit 40,4 Millionen Dollar an Direktverkäufen einen wesentlichen Beitrag, während die Verkäufe von Primatene MIST® um 5% auf 26,1 Millionen Dollar stiegen. Der Vorstand genehmigte eine Erhöhung um 50 Millionen Dollar für das Aktienrückkaufprogramm. Der operative Cashflow für die ersten neun Monate betrug 184,4 Millionen Dollar.
- Net revenues increased 6% YoY to $191.2 million
- BAQSIMI® generated $40.4 million in direct sales
- Primatene MIST® sales grew 5% to $26.1 million
- Strong operating cash flow of $184.4 million for nine months
- $50 million increase in share buyback program authorization
- GAAP net income decreased from $49.2M to $40.4M YoY
- Gross margin declined from 60.0% to 53.3%
- Enoxaparin sales decreased 27% to $5.6 million
- R&D expenses increased 26% to $21.1 million
- Other revenues decreased 92% to $2.4 million
Insights
Q3 results show mixed performance with
Pipeline developments are promising with 4 ANDAs targeting
Product portfolio transition shows strategic shift toward higher-value segments. Primatene MIST trending toward
R&D investment in insulin pipeline and biosimilars aligns with high-growth market opportunities. However, increased operating expenses and cost pressures could impact near-term profitability. The delayed
Reports Net Revenues of
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024.
Third quarter Highlights
Net revenues of
$191.2 million for the third quarterGAAP net income of
$40.4 million , or$0.78 per share, for the third quarterAdjusted non-GAAP net income of
$49.6 million , or$0.96 per share, for the third quarter
Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar has continued its growth this quarter, highlighted by sales, particularly from BAQSIMI®, which has become a cornerstone in our portfolio, and Primatene MIST®, which is trending toward our goal of
|
| Three Months Ended |
|
| Nine Months Ended | ||||||||||
|
| September 30, |
|
| September 30, | ||||||||||
|
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 | ||||
|
| (in thousands, except per share data) | |||||||||||||
Net revenues |
| $ | 191,214 |
|
| $ | 180,556 |
|
| $ | 545,444 |
|
| $ | 466,290 |
GAAP net income |
| $ | 40,429 |
|
| $ | 49,222 |
|
| $ | 121,555 |
|
| $ | 101,378 |
Adjusted non-GAAP net income* |
| $ | 49,585 |
|
| $ | 61,898 |
|
| $ | 153,569 |
|
| $ | 128,823 |
GAAP diluted EPS |
| $ | 0.78 |
|
| $ | 0.91 |
|
| $ | 2.32 |
|
| $ | 1.91 |
Adjusted non-GAAP diluted EPS* |
| $ | 0.96 |
|
| $ | 1.15 |
|
| $ | 2.94 |
|
| $ | 2.43 |
____________________________________
* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.
Third quarter Results
|
| Three Months Ended |
|
|
|
|
|
|
| |||||||
|
| September 30, |
|
| Change |
| ||||||||||
|
| 2024 |
|
| 2023 |
|
| Dollars |
|
| % |
| ||||
|
| (in thousands) |
|
|
|
| ||||||||||
Product revenues: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
BAQSIMI® |
| $ | 40,409 |
|
| $ | - |
|
| $ | 40,409 |
|
|
| N/A |
|
Glucagon |
|
| 26,792 |
|
|
| 29,514 |
|
|
| (2,722 | ) |
|
| (9 | )% |
Primatene MIST® |
|
| 26,055 |
|
|
| 24,834 |
|
|
| 1,221 |
|
|
| 5 | % |
Epinephrine |
|
| 21,341 |
|
|
| 20,199 |
|
|
| 1,142 |
|
|
| 6 | % |
Lidocaine |
|
| 15,884 |
|
|
| 15,522 |
|
|
| 362 |
|
|
| 2 | % |
Phytonadione |
|
| 11,721 |
|
|
| 7,449 |
|
|
| 4,272 |
|
|
| 57 | % |
Enoxaparin |
|
| 5,615 |
|
|
| 7,702 |
|
|
| (2,087 | ) |
|
| (27 | )% |
Naloxone |
|
| 4,037 |
|
|
| 4,715 |
|
|
| (678 | ) |
|
| (14 | )% |
Other finished pharmaceutical products |
|
| 35,503 |
|
|
| 37,730 |
|
|
| (2,227 | ) |
|
| (6 | )% |
Total finished pharmaceutical products net revenues |
| $ | 187,357 |
|
| $ | 147,665 |
|
| $ | 39,692 |
|
|
| 27 | % |
API |
|
| 1,462 |
|
|
| 4,190 |
|
|
| (2,728 | ) |
|
| (65 | )% |
Other revenues |
|
| 2,395 |
|
|
| 28,701 |
|
|
| (26,306 | ) |
|
| (92 | )% |
Total net revenues |
| $ | 191,214 |
|
| $ | 180,556 |
|
| $ | 10,658 |
|
|
| 6 | % |
Changes in product revenues as compared to the third quarter of the prior year were primarily driven by:
BAQSIMI® revenues consisting of
$40.4 million in sales made by the Company directly to its customers, which are recorded as part of product revenues, net, and$6.4 million in sales made by Eli Lilly & Company, or Lilly, on behalf of the Company under a Transition Services Agreement, or TSA, which resulted in a net payment to the Company of$2.4 million after deducting the cost of sales and other expenses and was recorded in other revenuesGlucagon sales decreased due to a decrease in unit volumes as a result of a move to ready to use glucagon products such as BAQSIMI®, as well as a decrease in average selling price
Primatene MIST® sales increased primarily due to an increase in unit volumes
Epinephrine sales increased primarily due to sales of epinephrine pre-filled syringes in Canada, which we began this quarter
The increase in sales of phytonadione was primarily due to an increase in unit volume, as a result of an increase in demand during the quarter
Enoxaparin and naloxone sales decreased primarily due to a decrease in unit volumes
Other finished pharmaceutical product sales changes were primarily due to:
Lower unit sales of atropine and calcium chloride, as a result of other suppliers returning to their historical distribution levels
These decreases were partially offset by:
Higher unit volumes of sodium bicarbonate due to an increase in capacity at our subsidiary, International Medication Systems, Limited
The launch of albuterol in August 2024
Between
|
| Three Months Ended |
|
|
|
|
|
|
| |||||||
|
| September 30, |
|
| Change |
| ||||||||||
|
| 2024 |
|
| 2023 |
|
| Dollars |
|
| % |
| ||||
|
| (in thousands) |
|
|
|
| ||||||||||
Net revenues |
| $ | 191,214 |
|
| $ | 180,556 |
|
| $ | 10,658 |
|
|
| 6 | % |
Cost of revenues |
|
| 89,273 |
|
|
| 72,153 |
|
|
| 17,120 |
|
|
| 24 | % |
Gross profit |
| $ | 101,941 |
|
| $ | 108,403 |
|
| $ | (6,462 | ) |
|
| (6 | )% |
as % of net revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in the cost of revenues and gross margin were primarily driven by:
Increased labor costs and certain component costs, as well as charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value
Decrease in other revenues related to Lilly's sales of BAQSIMI® under the TSA, which are recorded net of cost of sales and other expenses as we assumed distribution of BAQSIMI® to our customers and are now recording those sales in product revenues and cost of sales separately
This was partially offset by:
Increase in sales of Primatene MIST® and epinephrine, which are higher-margin products
|
| Three Months Ended |
|
|
|
|
|
|
| |||||||
|
| September 30, |
|
| Change |
| ||||||||||
|
| 2024 |
|
| 2023 |
|
| Dollars |
|
| % |
| ||||
|
| (in thousands) |
|
|
|
| ||||||||||
Selling, distribution, and marketing |
| $ | 8,995 |
|
| $ | 6,407 |
|
| $ | 2,588 |
|
|
| 40 | % |
General and administrative |
|
| 14,821 |
|
|
| 12,654 |
|
|
| 2,167 |
|
|
| 17 | % |
Research and development |
|
| 21,077 |
|
|
| 16,664 |
|
|
| 4,413 |
|
|
| 26 | % |
Selling, distribution, and marketing expenses increased primarily due to the expenses related to the expansion of our sales and marketing efforts related to BAQSIMI®
General and administrative expenses increased primarily due to an increase in salary and personnel-related expenses and expenses related to BAQSIMI®
Research and development expenses increased due to expenditure on raw materials and components for our insulin pipeline products, as well as an increase in salary and personnel-related expenses, which was partially offset by a decrease in clinical trial expenses due to the timing of clinical trials
|
| Three Months Ended |
|
|
|
|
|
|
| |||||||
|
| September 30, |
|
| Change |
| ||||||||||
|
| 2024 |
|
| 2023 |
|
| Dollars |
|
| % |
| ||||
|
| (in thousands) |
|
|
|
| ||||||||||
Non-operating income (expenses) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest income |
| $ | 2,427 |
|
| $ | 1,202 |
|
| $ | 1,225 |
|
|
| 102 | % |
Interest expense |
|
| (6,698 | ) |
|
| (13,702 | ) |
|
| 7,004 |
|
|
| (51 | )% |
Other income (expenses), net |
|
| (5,094 | ) |
|
| 3,459 |
|
|
| (8,553 | ) |
|
| (247 | )% |
Total non-operating income (expenses), net |
| $ | (9,365 | ) |
| $ | (9,041 | ) |
| $ | (324 | ) |
|
| 4 | % |
The change in non-operating income (expenses), net is primarily a result of:
An increase in interest income resulting from an increase in cash and investments
A decrease in interest expense was primarily due to the
$250.0 million repayment of the principal balance of the Wells Fargo Term Loan in September 2023, along with the write-off of unamortized debt issuance costs related to the Term Loan in 2023A change to other income (expenses), net primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts
Cash flow provided by operating activities for the nine months ended September 30, 2024, was
Share Buyback Program
On November 4, 2024, the Company's Board of Directors authorized a
Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws.
The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.
Pipeline Information
The Company currently has four abbreviated new drug applications ("ANDAs") on file with the U.S. Food and Drug Administration (the "FDA") targeting products with a market size of over
Amphastar's Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Co., Ltd. ("ANP"), currently has multiple Drug Master Files ("DMFs") on file with the FDA and is developing several additional DMFs.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVYTM, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which exclude amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI®, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.
Conference Call Information
The Company will hold a conference call to discuss its financial results today, November 6, 2024, at 2:00 p.m. Pacific Time.
To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website at www.amphastar.com.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI®, including its potential for continued revenue growth, the success of our integration of BAQSIMI®, the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful, that demand will be sufficient for us to meet our sales goal for Primatene MIST® or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416
Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)
|
| Three Months Ended |
|
| Nine Months Ended |
| ||||||||||
|
| September 30, |
|
| September 30, |
| ||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| |||||
Net revenues: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Product revenues, net |
| $ | 188,819 |
|
| $ | 151,855 |
|
| $ | 525,836 |
|
| $ | 437,589 |
|
Other revenues |
|
| 2,395 |
|
|
| 28,701 |
|
|
| 19,608 |
|
|
| 28,701 |
|
Total net revenues |
|
| 191,214 |
|
|
| 180,556 |
|
|
| 545,444 |
|
|
| 466,290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues |
|
| 89,273 |
|
|
| 72,153 |
|
|
| 258,237 |
|
|
| 211,309 |
|
Gross profit |
|
| 101,941 |
|
|
| 108,403 |
|
|
| 287,207 |
|
|
| 254,981 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, distribution, and marketing |
|
| 8,995 |
|
|
| 6,407 |
|
|
| 27,378 |
|
|
| 20,234 |
|
General and administrative |
|
| 14,821 |
|
|
| 12,654 |
|
|
| 43,782 |
|
|
| 38,418 |
|
Research and development |
|
| 21,077 |
|
|
| 16,664 |
|
|
| 55,772 |
|
|
| 53,322 |
|
Total operating expenses |
|
| 44,893 |
|
|
| 35,725 |
|
|
| 126,932 |
|
|
| 111,974 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations |
|
| 57,048 |
|
|
| 72,678 |
|
|
| 160,275 |
|
|
| 143,007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-operating income (expenses): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
| 2,427 |
|
|
| 1,202 |
|
|
| 8,320 |
|
|
| 3,156 |
|
Interest expense |
|
| (6,698 | ) |
|
| (13,702 | ) |
|
| (23,918 | ) |
|
| (17,702 | ) |
Other income (expenses), net |
|
| (5,094 | ) |
|
| 3,459 |
|
|
| 1,125 |
|
|
| 1,553 |
|
Total non-operating income (expenses), net |
|
| (9,365 | ) |
|
| (9,041 | ) |
|
| (14,473 | ) |
|
| (12,993 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
| 47,683 |
|
|
| 63,637 |
|
|
| 145,802 |
|
|
| 130,014 |
|
Income tax provision |
|
| 7,254 |
|
|
| 14,025 |
|
|
| 23,674 |
|
|
| 27,160 |
|
Net income before equity in losses of unconsolidated affiliate |
|
| 40,429 |
|
|
| 49,612 |
|
|
| 122,128 |
|
|
| 102,854 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity in losses of unconsolidated affiliate |
|
| - |
|
|
| (390 | ) |
|
| (573 | ) |
|
| (1,476 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
| $ | 40,429 |
|
| $ | 49,222 |
|
| $ | 121,555 |
|
| $ | 101,378 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
| $ | 0.83 |
|
| $ | 1.01 |
|
| $ | 2.50 |
|
| $ | 2.10 |
|
Diluted |
| $ | 0.78 |
|
| $ | 0.91 |
|
| $ | 2.32 |
|
| $ | 1.91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used to compute net income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
| 48,621 |
|
|
| 48,701 |
|
|
| 48,580 |
|
|
| 48,368 |
|
Diluted |
|
| 51,862 |
|
|
| 53,921 |
|
|
| 52,307 |
|
|
| 52,997 |
|
Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; in thousands, except share data)
|
| September 30, |
|
| December 31, |
| ||
|
| 2024 |
|
| 2023 |
| ||
|
| (unaudited) |
|
|
|
| ||
ASSETS |
|
|
|
|
|
| ||
Current assets: |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 192,116 |
|
| $ | 144,296 |
|
Restricted cash |
|
| 235 |
|
|
| 235 |
|
Short-term investments |
|
| 58,375 |
|
|
| 112,510 |
|
Restricted short-term investments |
|
| 2,200 |
|
|
| 2,200 |
|
Accounts receivable, net |
|
| 139,635 |
|
|
| 114,943 |
|
Inventories |
|
| 130,316 |
|
|
| 105,833 |
|
Income tax refunds and deposits |
|
| 5,349 |
|
|
| 526 |
|
Prepaid expenses and other assets |
|
| 17,723 |
|
|
| 9,057 |
|
Total current assets |
|
| 545,949 |
|
|
| 489,600 |
|
|
|
|
|
|
|
|
|
|
Property, plant, and equipment, net |
|
| 295,384 |
|
|
| 282,746 |
|
Finance lease right-of-use assets |
|
| 426 |
|
|
| 564 |
|
Operating lease right-of-use assets |
|
| 31,708 |
|
|
| 32,333 |
|
Investment in unconsolidated affiliate |
|
| - |
|
|
| 527 |
|
Goodwill and intangible assets, net |
|
| 594,796 |
|
|
| 613,295 |
|
Long-term investments |
|
| - |
|
|
| 14,685 |
|
Other assets |
|
| 23,663 |
|
|
| 25,910 |
|
Deferred tax assets |
|
| 53,252 |
|
|
| 53,252 |
|
Total assets |
| $ | 1,545,178 |
|
| $ | 1,512,912 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
| $ | 153,268 |
|
| $ | 93,366 |
|
Accrued payments for BAQSIMI® |
|
| - |
|
|
| 126,090 |
|
Income taxes payable |
|
| 1,281 |
|
|
| 1,609 |
|
Current portion of long-term debt |
|
| 252 |
|
|
| 436 |
|
Current portion of operating lease liabilities |
|
| 4,209 |
|
|
| 3,906 |
|
Total current liabilities |
|
| 159,010 |
|
|
| 225,407 |
|
|
|
|
|
|
|
|
|
|
Long-term reserve for income tax liabilities |
|
| 6,066 |
|
|
| 6,066 |
|
Long-term debt, net of current portion and unamortized debt issuance costs |
|
| 596,446 |
|
|
| 589,579 |
|
Long-term operating lease liabilities, net of current portion |
|
| 28,941 |
|
|
| 29,721 |
|
Other long-term liabilities |
|
| 27,037 |
|
|
| 22,718 |
|
Total liabilities |
|
| 817,500 |
|
|
| 873,491 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
Preferred stock: par value |
|
| - |
|
|
| - |
|
Common stock: par value |
|
| 6 |
|
|
| 6 |
|
Additional paid-in capital |
|
| 496,427 |
|
|
| 486,056 |
|
Retained earnings |
|
| 530,823 |
|
|
| 409,268 |
|
Accumulated other comprehensive loss |
|
| (8,821 | ) |
|
| (8,478 | ) |
Treasury stock |
|
| (290,757 | ) |
|
| (247,431 | ) |
Total equity |
|
| 727,678 |
|
|
| 639,421 |
|
Total liabilities and stockholders' equity |
| $ | 1,545,178 |
|
| $ | 1,512,912 |
|
Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)
|
| Three Months Ended |
|
| Nine Months Ended |
| ||||||||||
|
| September 30, |
|
| September 30, |
| ||||||||||
|
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
GAAP net income |
| $ | 40,429 |
|
| $ | 49,222 |
|
| $ | 121,555 |
|
| $ | 101,378 |
|
Adjusted for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset amortization |
|
| 6,179 |
|
|
| 6,168 |
|
|
| 18,539 |
|
|
| 6,651 |
|
Share-based compensation |
|
| 5,596 |
|
|
| 4,644 |
|
|
| 18,736 |
|
|
| 15,620 |
|
Impairment of long-lived assets |
|
| - |
|
|
| 474 |
|
|
| - |
|
|
| 3,174 |
|
Expenses related to BAQSIMI® acquisition |
|
| - |
|
|
| 2,182 |
|
|
| 3,651 |
|
|
| 3,682 |
|
Debt issuance costs |
|
| - |
|
|
| 3,019 |
|
|
| - |
|
|
| 6,043 |
|
Income tax provision on pre-tax adjustments |
|
| (2,619 | ) |
|
| (3,811 | ) |
|
| (8,912 | ) |
|
| (7,725 | ) |
Adjusted non-GAAP net income |
| $ | 49,585 |
|
| $ | 61,898 |
|
| $ | 153,569 |
|
| $ | 128,823 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted non-GAAP net income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
| $ | 1.02 |
|
| $ | 1.27 |
|
| $ | 3.16 |
|
| $ | 2.66 |
|
Diluted |
| $ | 0.96 |
|
| $ | 1.15 |
|
| $ | 2.94 |
|
| $ | 2.43 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used to compute adjusted non-GAAP net income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
| 48,621 |
|
|
| 48,701 |
|
|
| 48,580 |
|
|
| 48,368 |
|
Diluted |
|
| 51,862 |
|
|
| 53,921 |
|
|
| 52,307 |
|
|
| 52,997 |
|
|
| Three Months Ended September 30, 2024 |
| |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
| Selling, |
|
| General |
|
| Research |
|
| Non-operating |
|
|
|
| ||||||
|
| Cost of |
|
| distribution |
|
| and |
|
| and |
|
| (expenses) |
|
| Income |
| ||||||
|
| revenue |
|
| and marketing |
|
| administrative |
|
| development |
|
| income, net |
|
| tax provision |
| ||||||
GAAP |
| $ | 89,273 |
|
| $ | 8,995 |
|
| $ | 14,821 |
|
| $ | 21,077 |
|
| $ | (9,365 | ) |
| $ | 7,254 |
|
Intangible asset amortization |
|
| (6,159 | ) |
|
| - |
|
|
| (1 | ) |
|
| (19 | ) |
|
| - |
|
|
| - |
|
Share-based compensation |
|
| (1,133 | ) |
|
| (249 | ) |
|
| (3,710 | ) |
|
| (504 | ) |
|
| - |
|
|
| - |
|
Income tax provision on pre-tax adjustments |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 2,619 |
|
Non-GAAP |
| $ | 81,981 |
|
| $ | 8,746 |
|
| $ | 11,110 |
|
| $ | 20,554 |
|
| $ | (9,365 | ) |
| $ | 9,873 |
|
|
| Three Months Ended September 30, 2023 |
| |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
| Selling, |
|
| General |
|
| Research |
|
| Non-operating |
|
|
|
| ||||||
|
| Cost of |
|
| distribution |
|
| and |
|
| and |
|
| (expenses) |
|
| Income |
| ||||||
|
| revenue |
|
| and marketing |
|
| administrative |
|
| development |
|
| income, net |
|
| tax provision |
| ||||||
GAAP |
| $ | 72,153 |
|
| $ | 6,407 |
|
| $ | 12,654 |
|
| $ | 16,664 |
|
| $ | (9,041 | ) |
| $ | 14,025 |
|
Intangible asset amortization |
|
| (6,149 | ) |
|
| - |
|
|
| 34 |
|
|
| (53 | ) |
|
| - |
|
|
| - |
|
Share-based compensation |
|
| (1,004 | ) |
|
| (213 | ) |
|
| (2,975 | ) |
|
| (452 | ) |
|
| - |
|
|
| - |
|
Impairment of long-lived assets |
|
| (470 | ) |
|
| - |
|
|
| (4 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
Expenses related to BAQSIMI® acquisition |
|
| - |
|
|
| - |
|
|
| (357 | ) |
|
| - |
|
|
| 1,825 |
|
|
| - |
|
Debt issuance costs |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 3,019 |
|
|
| - |
|
Income tax provision on pre-tax adjustments |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 3,811 |
|
Non-GAAP |
| $ | 64,530 |
|
| $ | 6,194 |
|
| $ | 9,352 |
|
| $ | 16,159 |
|
| $ | (4,197 | ) |
| $ | 17,836 |
|
|
| Nine Months Ended September 30, 2024 |
| |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
| Selling, |
|
| General |
|
| Research |
|
| Non-operating |
|
|
|
| ||||||
|
| Cost of |
|
| distribution |
|
| and |
|
| and |
|
| (expenses) |
|
| Income |
| ||||||
|
| revenue |
|
| and marketing |
|
| administrative |
|
| development |
|
| income, net |
|
| tax provision |
| ||||||
GAAP |
| $ | 258,237 |
|
| $ | 27,378 |
|
| $ | 43,782 |
|
| $ | 55,772 |
|
| $ | (14,473 | ) |
| $ | 23,674 |
|
Intangible asset amortization |
|
| (18,479 | ) |
|
| - |
|
|
| (4 | ) |
|
| (56 | ) |
|
| - |
|
|
| - |
|
Share-based compensation |
|
| (4,583 | ) |
|
| (777 | ) |
|
| (11,239 | ) |
|
| (2,137 | ) |
|
| - |
|
|
| - |
|
Expenses related to BAQSIMI® acquisition |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 3,651 |
|
|
| - |
|
Income tax provision on pre-tax adjustments |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 8,912 |
|
Non-GAAP |
| $ | 235,175 |
|
| $ | 26,601 |
|
| $ | 32,539 |
|
| $ | 53,579 |
|
| $ | (10,822 | ) |
| $ | 32,586 |
|
|
| Nine Months Ended September 30, 2023 |
| |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
| Selling, |
|
| General |
|
| Research |
|
| Non-operating |
|
|
|
| ||||||
|
| Cost of |
|
| distribution |
|
| and |
|
| and |
|
| (expenses) |
|
| Income |
| ||||||
|
| revenue |
|
| and marketing |
|
| administrative |
|
| development |
|
| income, net |
|
| tax provision |
| ||||||
GAAP |
| $ | 211,309 |
|
| $ | 20,234 |
|
| $ | 38,418 |
|
| $ | 53,322 |
|
| $ | (12,993 | ) |
| $ | 27,160 |
|
Intangible asset amortization |
|
| (6,582 | ) |
|
| - |
|
|
| (16 | ) |
|
| (53 | ) |
|
| - |
|
|
| - |
|
Share-based compensation |
|
| (3,868 | ) |
|
| (649 | ) |
|
| (9,323 | ) |
|
| (1,780 | ) |
|
| - |
|
|
| - |
|
Impairment of long-lived assets |
|
| (3,170 | ) |
|
| - |
|
|
| (4 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
Expenses related to BAQSIMI® acquisition |
|
| - |
|
|
| - |
|
|
| (1,857 | ) |
|
| - |
|
|
| 1,825 |
|
|
| - |
|
Debt issuance costs |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 6,043 |
|
|
| - |
|
Income tax provision on pre-tax adjustments |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 7,725 |
|
Non-GAAP |
| $ | 197,689 |
|
| $ | 19,585 |
|
| $ | 27,218 |
|
| $ | 51,489 |
|
| $ | (5,125 | ) |
| $ | 34,885 |
|
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What was Amphastar's (AMPH) revenue in Q3 2024?
How much did BAQSIMI contribute to Amphastar's (AMPH) Q3 2024 revenue?
What was Amphastar's (AMPH) earnings per share in Q3 2024?